Can IVIG Intervene in AD? Insights from Animal Experiments and Clinical Trials-A Systematic Review and Synthesis...

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Intravenous immunoglobulin (IVIG) is a potential
• one-drug, multi-target
• therapy for Alzheimer's disease (AD).

Purpose of the Study:

• To systematically review existing animal and clinical trials on IVIG for AD.
• To provide insights for future IVIG-based therapeutic development.

Main Methods:

• Systematic literature search across multiple databases (PubMed, Embase, etc.) up to October 2025.
• Analysis of studies using terms related to Alzheimer's, IVIG, and beta-amyloid protein.

Main Results:

• IVIG demonstrated clinical safety in AD treatment, with varied methodologies across studies.
• IVIG generally delayed cognitive decline in AD mice and patients.
• IVIG showed potential for peripheral clearance of amyloid-beta (Aβ) and tau, reduced brain atrophy, and plaque reduction.
• Combination therapy with plasma exchange (PE) enhanced IVIG's benefits in language, memory, and praxis.

Conclusions:

• IVIG has a favorable safety profile and can ameliorate AD symptoms, but efficacy varies.
• Future research should address efficacy variations and standardize preclinical IVIG evaluation for AD.
• Development of specific IVIG products for AD is warranted.